Article

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in <i>KRAS</i> -mutant Pancreatic and Lung Cancer

2026-08-11

Abstract excerpt

<h4>ABSTRACT</h4> Resistance limits the clinical efficacy of RAS inhibitors. We applied chemical and genetic screens and identified the AXL receptor tyrosine kinase as a driver of resistance to RAS-ERK inhibition. We determined that combination treatment with the AXL inhibitor bemcentinib (AXLi) together with the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 (RASi) or the ERK-selective inhibitor SCH77298...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7074c08-7458-5b90-8b37-41f525c8d386
DOI: 10.64898/2026.08.10.743026

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in <i>KRAS</i> -mutant Pancreatic and Lung CancerDOI 10.64898/2026.08.10.743026Read

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerSemantic proximity Read

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.Semantic proximity Read

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read

Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaSemantic proximity Read

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read

Identification of drug resistance mechanisms induced in response to KRAS therapeuticsSemantic proximity Read

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer.Semantic proximity Read